Visirna Therapeutics

Visirna Therapeutics is a biotechnology company focused on Arrowhead's four cardiometabolic disease therapies, developing RNAi-based treatments. It is a joint venture established by Arrowhead Pharmaceuticals and global healthcare investment firm Vivo Capital.